NumerixS Investment Technologies Inc Trims Stock Position in Beigene Ltd (NASDAQ:BGNE)
NumerixS Investment Technologies Inc lessened its holdings in shares of Beigene Ltd (NASDAQ:BGNE) by 44.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,900 shares of the company’s stock after selling 1,500 shares during the period. NumerixS Investment Technologies Inc’s holdings in Beigene were worth $236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of BGNE. Myriad Asset Management Ltd. purchased a new position in shares of Beigene during the second quarter worth $70,734,000. New Silk Road Investment PTE Ltd. purchased a new position in shares of Beigene during the second quarter worth $15,292,000. Geode Capital Management LLC raised its holdings in shares of Beigene by 418.8% during the fourth quarter. Geode Capital Management LLC now owns 134,057 shares of the company’s stock worth $18,629,000 after purchasing an additional 108,218 shares during the last quarter. BlackRock Inc. raised its holdings in shares of Beigene by 4.6% during the second quarter. BlackRock Inc. now owns 2,012,477 shares of the company’s stock worth $249,447,000 after purchasing an additional 88,827 shares during the last quarter. Finally, Matthews International Capital Management LLC raised its holdings in shares of Beigene by 28.6% during the second quarter. Matthews International Capital Management LLC now owns 300,303 shares of the company’s stock worth $37,184,000 after purchasing an additional 66,700 shares during the last quarter.
Shares of NASDAQ BGNE traded up $1.79 during trading on Thursday, hitting $132.69. The company had a trading volume of 7,102 shares, compared to its average volume of 389,915. The stock has a fifty day simple moving average of $136.69 and a two-hundred day simple moving average of $130.59. Beigene Ltd has a fifty-two week low of $105.19 and a fifty-two week high of $179.57. The firm has a market capitalization of $6.27 billion, a price-to-earnings ratio of -10.92 and a beta of 1.02. The company has a quick ratio of 6.28, a current ratio of 6.46 and a debt-to-equity ratio of 0.15.
BGNE has been the subject of several recent research reports. Piper Jaffray Companies reissued a “buy” rating on shares of Beigene in a report on Thursday, June 20th. Cowen reaffirmed a “buy” rating and issued a $170.00 price objective on shares of Beigene in a report on Friday, May 31st. ValuEngine raised shares of Beigene from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Zacks Investment Research cut shares of Beigene from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. Finally, Macquarie started coverage on shares of Beigene in a report on Friday, July 5th. They issued an “underperform” rating for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $181.28.
In other Beigene news, Director Timothy Yung-Cheng Chen sold 8,614 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $144.96, for a total value of $1,248,685.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO John Oyler sold 3,106 shares of the business’s stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $126.87, for a total transaction of $394,058.22. Following the completion of the transaction, the chief executive officer now owns 17,221,155 shares in the company, valued at $2,184,847,934.85. The disclosure for this sale can be found here. Insiders sold a total of 38,365 shares of company stock worth $4,478,041 over the last quarter. 13.40% of the stock is currently owned by company insiders.
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Recommended Story: Candlestick
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.